Title |
Economic evaluation of Zepatier for the management of HCV in the Italian scenario
|
---|---|
Published in |
HEPAC Health Economics in Prevention and Care, April 2018
|
DOI | 10.1007/s10198-018-0980-4 |
Pubmed ID | |
Authors |
F. R. Rolli, M. Ruggeri, F. Kheiraoui, C. Drago, M. Basile, C. Favaretti, A. Cicchetti |
Abstract |
Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections. Conducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis). A Markov model was built on the natural history of the disease to assess the efficacy of the alternatives. The outcomes are expressed in terms of quality adjusted life-years (QALYs) and result in terms of incremental cost-effectiveness ratio). Elbasvir/grazoprevir implies an expenditure of €21,104,253.74 with a gain of 19,287.90 QALYs and sofosbuvir + pegylated interferon/ribavirin implies an expenditure of €31,904,410.11 with a gain of 18,855.96 QALYs. Elbasvir/grazoprevir is thus a dominant strategy. Consideration should be given to the opportunity cost of not treating patients with a lower degree of fibrosis (F0-F2). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 2 | 13% |
Student > Master | 2 | 13% |
Student > Postgraduate | 2 | 13% |
Student > Ph. D. Student | 2 | 13% |
Researcher | 2 | 13% |
Other | 2 | 13% |
Unknown | 4 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 31% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Immunology and Microbiology | 1 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 6% |
Chemistry | 1 | 6% |
Other | 1 | 6% |
Unknown | 6 | 38% |